Focus: Glaukos is a publicly traded ophthalmology-focused medical device company specializing in glaucoma treatments, operating at a mid-cap biotech scale with $315M in FY2025 revenue.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Glaukos to get notified when they start hiring — the background below is worth knowing for when they do.
MITOMYCIN accounts for 50% of company revenue but is a post-LOE generic with minimal pricing power; erosion is inevitable.
Help build intelligence for Glaukos
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Glaukos's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Novel sustained-release implant in growth phase with patent protection until 2031; represents core innovation strategy in glaucoma.
Peak-stage corneal cross-linking therapy; expands portfolio beyond glaucoma into keratoconus and ectasia markets.
Riboflavin-based therapy approaching loss of exclusivity in 2028; indicates need for pipeline advancement in this category.
2 discontinued, 6 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo